See more : TFF Group (TFF.PA) Income Statement Analysis – Financial Results
Complete financial analysis of PTC Therapeutics, Inc. (PTCT) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of PTC Therapeutics, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
- Trilogy International Partners Inc. (TRL.TO) Income Statement Analysis – Financial Results
- AMCI Acquisition Corp. II (AMCI) Income Statement Analysis – Financial Results
- WH Ireland Group plc (WHI.L) Income Statement Analysis – Financial Results
- Tongyang Inc. (001529.KS) Income Statement Analysis – Financial Results
- Minto Metals Corp. (MNTO.V) Income Statement Analysis – Financial Results
PTC Therapeutics, Inc. (PTCT)
About PTC Therapeutics, Inc.
PTC Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines to patients with rare disorders. Its portfolio pipeline includes commercial products and product candidates in various stages of development, including clinical, pre-clinical and research and discovery stages, focuses on the development of treatments for multiple therapeutic areas, such as rare diseases. The company offers Translarna and Emflaza for the treatment of Duchenne muscular dystrophy in the European Economic Area and the United States, as well as to treat nonsense mutation Duchenne muscular dystrophy in Brazil and Russia; commercializes Tegsedi and Waylivra for the treatment of rare diseases in Latin America and the Caribbean; and markets Evrysdi for the treatment of spinal muscular atrophy in adults and children two months and older in Brazil. The company's splicing platform includes PTC518, which is being developed for the treatment of Huntington's disease. PTC Therapeutics, Inc. has collaborations with F. Hoffman-La Roche Ltd and Hoffman-La Roche Inc., as well as the Spinal Muscular Atrophy Foundation to advance drug discovery and development research in regenerative medicine; and Akcea Therapeutics, Inc. to commercialize Tegsedi and Waylivra for the treatment of rare diseases in Latin America and the Caribbean. PTC Therapeutics, Inc. was incorporated in 1998 and is headquartered in South Plainfield, New Jersey.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 937.82M | 698.80M | 538.59M | 380.77M | 306.98M | 264.73M | 194.39M | 82.71M | 36.77M | 22.96M | 31.33M | 28.78M | 98.96M |
| Cost of Revenue | 65.49M | 44.68M | 32.33M | 18.94M | 12.14M | 12.67M | 4.58M | 117.63M | 121.82M | 79.84M | 54.88M | -5.17M | 0.00 |
| Gross Profit | 872.34M | 654.12M | 506.27M | 361.82M | 294.85M | 252.06M | 189.82M | -34.93M | -85.05M | -56.88M | -23.55M | 33.95M | 98.96M |
| Gross Profit Ratio | 93.02% | 93.61% | 94.00% | 95.03% | 96.05% | 95.21% | 97.65% | -42.23% | -231.33% | -247.68% | -75.17% | 117.95% | 100.00% |
| Research & Development | 666.56M | 651.50M | 540.68M | 477.64M | 257.45M | 171.98M | 117.46M | 117.63M | 121.82M | 79.84M | 54.88M | 46.14M | 58.68M |
| General & Administrative | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 153.55M | 121.27M | 97.13M | 82.08M | 44.82M | 25.22M | 14.62M | 16.15M |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 332.54M | 326.00M | 285.77M | 245.16M | 202.54M | 153.55M | 121.27M | 97.13M | 82.08M | 44.82M | 25.22M | 14.62M | 16.15M |
| Other Expenses | 0.00 | 116.55M | 54.75M | 36.89M | 27.65M | 129.00K | -1.28M | -1.21M | -465.00K | -213.00K | 37.51K | 1.78M | 461.36K |
| Operating Expenses | 1.31B | 1.09B | 881.21M | 759.70M | 487.64M | 348.41M | 254.11M | 214.76M | 203.90M | 122.38M | 76.72M | 55.59M | 68.38M |
| Cost & Expenses | 1.29B | 1.14B | 913.54M | 778.64M | 499.78M | 361.08M | 258.68M | 214.76M | 203.90M | 122.38M | 76.72M | 55.59M | 68.38M |
| Interest Income | 0.00 | 90.87M | 86.02M | 56.35M | 12.49M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 129.18M | 90.87M | 86.02M | 56.35M | 12.49M | 12.55M | 12.09M | 8.28M | 2.37M | 1.18M | 0.00 | 0.00 | 2.44M |
| Depreciation & Amortization | 236.59M | 128.84M | 71.52M | 49.58M | 36.06M | 26.09M | 17.68M | 3.29M | 2.88M | 2.24M | 2.40M | 2.70M | 2.87M |
| EBITDA | -330.34M | -367.78M | -374.44M | -297.00M | -191.38M | -89.47M | -46.61M | -128.77M | -164.25M | -97.18M | -43.00M | -24.10M | 33.45M |
| EBITDA Ratio | -35.22% | -53.32% | -70.20% | -59.83% | -38.04% | -20.45% | -25.16% | -159.67% | -454.58% | -432.93% | -136.85% | -83.76% | 33.80% |
| Operating Income | -349.40M | -439.93M | -374.94M | -397.88M | -192.80M | -115.69M | -64.29M | -132.06M | -167.13M | -99.41M | -45.40M | -26.81M | 30.58M |
| Operating Income Ratio | -37.26% | -62.95% | -69.62% | -104.49% | -62.80% | -43.70% | -33.07% | -159.67% | -454.58% | -432.93% | -144.92% | -93.15% | 30.90% |
| Total Other Income/Expenses | -346.71M | -147.56M | -143.40M | -59.36M | -47.13M | -12.43M | -13.37M | -9.48M | -2.83M | 967.00K | -6.18M | 573.00K | -1.98M |
| Income Before Tax | -696.11M | -587.49M | -518.34M | -402.93M | -239.93M | -128.11M | -77.67M | -141.54M | -169.96M | -98.45M | -51.57M | -26.24M | 28.60M |
| Income Before Tax Ratio | -74.23% | -84.07% | -96.24% | -105.82% | -78.16% | -48.39% | -39.95% | -171.14% | -462.28% | -428.72% | -164.63% | -91.16% | 28.90% |
| Income Tax Expense | -69.51M | -28.47M | 5.56M | 35.23M | 11.65M | -29.00K | 1.34M | 569.00K | 485.00K | -4.69M | 6.21M | 1.21M | -2.31M |
| Net Income | -626.60M | -559.02M | -523.90M | -438.16M | -251.58M | -128.08M | -79.00M | -142.11M | -170.45M | -93.75M | -51.57M | -26.24M | 30.90M |
| Net Income Ratio | -66.81% | -80.00% | -97.27% | -115.07% | -81.95% | -48.38% | -40.64% | -171.83% | -463.60% | -408.28% | -164.63% | -91.16% | 31.23% |
| EPS | -8.37 | -7.79 | -7.43 | -6.64 | -4.27 | -2.75 | -2.02 | -4.17 | -5.07 | -2.97 | -4.02 | -1.85 | 0.00 |
| EPS Diluted | -8.37 | -7.79 | -7.43 | -6.64 | -4.27 | -2.75 | -2.02 | -4.17 | -5.07 | -2.97 | -4.02 | -1.11 | 0.00 |
| Weighted Avg Shares Out | 74.84M | 71.73M | 70.47M | 66.03M | 58.86M | 46.58M | 39.11M | 34.04M | 33.62M | 31.57M | 12.82M | 14.19M | 14.19M |
| Weighted Avg Shares Out (Dil) | 74.84M | 71.73M | 70.47M | 66.03M | 58.86M | 46.58M | 39.18M | 34.04M | 33.63M | 31.57M | 12.83M | 23.68M | 23.68M |
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of PTC Therapeutics, Inc. - PTCT
PTCT STOCKHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that PTC Therapeutics, Inc Investors with Losses Have Opportunity to Lead Class Action Lawsuit!
PTCT SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that PTC Therapeutics, Inc Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit!
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of PTC Therapeutics, Inc. - PTCT
Bronstein, Gewirtz and Grossman, LLC sends a Class Action Lawsuit reminder to shareholder investors for PTC Therapeutics, Inc to Lead the Class Action Lawsuit!
PTC Therapeutics, Inc. (PTCT) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Seek Compensation for Alleged Wrongdoings
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of PTC Therapeutics, Inc. - PTCT
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of PTC Therapeutics, Inc. - PTCT
PTC Therapeutics, Inc. (PTCT) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Seek Compensation for Alleged Wrongdoings
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of PTC Therapeutics, Inc. - PTCT
Source: https://incomestatements.info
Category: Stock Reports